GO:0072124 regulation of glomerular mesangial cell proliferation: Signaling Network, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0072124 describes any process that modulates the frequency, rate or extent of glomerular mesangial cell proliferation, a central event in mesangial proliferative glomerulonephritis and diabetic kidney disease.
• Mesangial cell proliferation is driven by growth factors, cytokines, metabolic stress and matrix-derived signals, and is tightly balanced by antiproliferative and proapoptotic pathways.
• Key regulators include NR4A1, YY1, HIF-1alpha, mitochondrial reactive oxygen species, and metabolic enzymes such as ASS1, PCK1 and CBR3.
• Dysregulated mesangial proliferation contributes to glomerulosclerosis, progressive loss of renal function and chronic kidney disease, including IgA nephropathy.
• Single-nucleus RNA-seq and other high-resolution approaches are revealing the cellular trajectories from onset to chronic kidney disease in IgA nephropathy.
• CRISPR-based knockout, point-mutation, knock-in and overexpression models are essential to establish causality for candidate regulators of mesangial cell proliferation.
Description
Glomerular mesangial cells are contractile, phagocytic cells that provide structural support to the glomerular capillary tuft and regulate filtration surface area. Their proliferation is a hallmark of many progressive kidney diseases, and the Gene Ontology term GO:0072124, regulation of glomerular mesangial cell proliferation, captures the biological processes that control this proliferative response. Understanding this term is critical because mesangial cell proliferation is not merely a histological finding but an active driver of glomerular injury, matrix accumulation and loss of renal function. Experimental studies have identified numerous soluble factors, including growth factors, cytokines and vasoactive peptides, that either promote or suppress mesangial cell proliferation in vitro and in vivo. More recent work has uncovered intracellular regulators such as nuclear receptor NR4A1, the transcription factor YY1, HIF-1alpha and mitochondrial reactive oxygen species that feed into proliferative signaling loops. Metabolic reprogramming, particularly arginine-proline metabolism, has also emerged as a key modulator of mesangioproliferative glomerulopathies. This article integrates authoritative GO annotation with verified PubMed literature to provide a research-grade overview of GO:0072124, its mechanistic basis, associated genes, disease relevance and the experimental models used to study it.
regulation of glomerular mesangial cell proliferation At A Glance
| GO ID | GO:0072124 |
|---|---|
| GO term | regulation of glomerular mesangial cell proliferation |
| Ontology | biological_process |
| Synonym | none |
| Major function | Modulation of the frequency, rate or extent of mesangial cell proliferation in the glomerulus |
| Cellular context | Glomerular mesangium, including mesangial cells and their extracellular matrix |
| Key upstream signals | Growth factors, cytokines, metabolic stress, mitochondrial ROS, transcription factors such as NR4A1, YY1 and HIF-1alpha |
| Disease relevance | Mesangial proliferative glomerulonephritis, diabetic kidney disease, IgA nephropathy and progressive glomerular injury |
| Research methods | In vitro mesangial cell culture, animal models, single-nucleus RNA-seq, CRISPR gene editing |
What Is GO:0072124?
GO:0072124, regulation of glomerular mesangial cell proliferation, is defined as any process that modulates the frequency, rate or extent of glomerular mesangial cell proliferation. In other words, it encompasses all molecular and cellular events that either stimulate or inhibit the division of mesangial cells within the glomerulus. This regulation can occur through growth factor signaling, cytokine networks, cell cycle control, metabolic cues and cell-matrix interactions.
Why Is regulation of glomerular mesangial cell proliferation Important in Cell Biology?
Regulation of glomerular mesangial cell proliferation is a central node in the pathogenesis of progressive kidney disease. Excessive or sustained mesangial proliferation leads to glomerular hypercellularity, matrix expansion and eventually glomerulosclerosis, which is a common final pathway in chronic kidney disease. Conversely, insufficient mesangial cell turnover may impair glomerular repair. Therefore, understanding the molecular switches that control this process is essential for identifying therapeutic targets and biomarkers. The term is also important for interpreting single-cell and spatial transcriptomics data from kidney biopsies, where mesangial cell proliferation signatures can distinguish active disease from chronic damage.
• Mesangial cell proliferation is a defining pathological feature of mesangial proliferative glomerulonephritis.
• It contributes to progressive glomerular injury and loss of renal function in both immune-mediated and metabolic kidney diseases.
• Key regulators such as NR4A1 protect against mesangial proliferation by avoiding ubiquitin-mediated degradation.
• The YY1/HIF-1alpha/mROS positive-feedback loop exacerbates mesangial cell proliferation in early diabetic kidney disease.
• Metabolic enzymes ASS1, PCK1 and CBR3 are dysregulated in mesangioproliferative glomerulopathies, linking arginine-proline metabolism to proliferation.
• Single-nucleus RNA-seq has revealed cellular trajectories from onset to chronic kidney disease in IgA nephropathy, highlighting mesangial cell states.
• In vitro and in vivo models have identified multiple growth factors and cytokines that regulate mesangial cell proliferation.
• The process is a potential therapeutic target for antiproliferative strategies in glomerular disease.
• CRISPR-based editing enables causal testing of candidate regulators in mesangial cells.
• Understanding this term aids in the interpretation of kidney biopsy transcriptomics and drug response.
What Happens During regulation of glomerular mesangial cell proliferation?
Initiation by growth factors and cytokines
In simple terms: Growth factors and cytokines act like keys that start the engine of mesangial cell division.
Mesangial cell proliferation is initiated by a variety of soluble mediators, including platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), interleukin-1 (IL-1), interleukin-6 (IL-6) and transforming growth factor-beta (TGF-beta), which are released during glomerular injury. These factors bind to their cognate receptors on mesangial cells and activate intracellular signaling cascades such as MAPK/ERK and PI3K/Akt, leading to cell cycle entry. In vivo studies have shown that infusion of these factors or induction of their expression can trigger mesangial proliferation, whereas neutralization reduces it.
Intracellular signaling and transcription factor activation
In simple terms: Inside the cell, signals are relayed to the nucleus where transcription factors switch on genes needed for division.
Upon receptor activation, multiple intracellular pathways converge on transcription factors that drive proliferation. For example, the transcription factor YY1, together with HIF-1alpha and mitochondrial reactive oxygen species (mROS), forms a positive-feedback loop that exacerbates mesangial cell proliferation in early diabetic kidney disease. Nuclear receptor NR4A1 is another key regulator; its ubiquitin-mediated degradation promotes mesangial proliferation, and protecting NR4A1 from degradation alleviates mesangial proliferative glomerulonephritis. These findings highlight that the balance between pro- and antiproliferative transcription factors determines the proliferative outcome.
Metabolic reprogramming and mitochondrial signals
In simple terms: Changes in how cells use nutrients and produce energy can push them to divide.
Metabolic pathways are increasingly recognized as regulators of mesangial cell proliferation. Dysregulation of argininosuccinate synthase 1 (ASS1), phosphoenolpyruvate carboxykinase 1 (PCK1) and carbonyl reductase 3 (CBR3) has been identified as key arginine-proline metabolic mediators in mesangioproliferative glomerulopathies. Mitochondrial reactive oxygen species (mROS) act as signaling molecules that feed into the YY1/HIF-1alpha loop, further driving proliferation. These metabolic and redox signals can modulate cell cycle progression and survival.
Cell cycle progression and proliferation
In simple terms: Once the signals are in place, cells move through the cell cycle and divide.
The ultimate outcome of these signaling events is the activation of cyclin-dependent kinases (CDKs) and progression through the G1/S and G2/M checkpoints, leading to DNA synthesis and mitosis. Mesangial cell proliferation in vitro and in vivo is characterized by increased DNA synthesis and cell number, which can be measured by thymidine incorporation or Ki-67 staining. The process is counterbalanced by antiproliferative signals, including TGF-beta at later stages, and by apoptosis, which together determine net mesangial cellularity.
Resolution and matrix remodeling
In simple terms: After proliferation, the glomerulus attempts to return to normal, but persistent injury leads to scarring.
In self-limited glomerular injury, mesangial proliferation resolves through apoptosis and clearance of excess matrix. However, in progressive disease, sustained proliferation leads to accumulation of extracellular matrix, glomerulosclerosis and loss of filtration function. The resolution phase involves antiproliferative factors and matrix metalloproteinases, while failure of resolution is associated with chronic kidney disease.
Key Genes Involved in GO:0072124 regulation of glomerular mesangial cell proliferation
The following genes and proteins have been experimentally implicated in the regulation of glomerular mesangial cell proliferation, based on verified PubMed literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NR4A1 | Nuclear receptor that protects against mesangial proliferation; its ubiquitin-mediated degradation promotes proliferation | Target for stabilizing drugs in mesangial proliferative glomerulonephritis |
| YY1 | Transcription factor that forms a positive-feedback loop with HIF-1alpha and mROS to exacerbate proliferation | Therapeutic target in early diabetic kidney disease |
| HIF-1alpha | Hypoxia-inducible factor that cooperates with YY1 and mROS to drive proliferation | Modulator of metabolic and proliferative responses in diabetic kidney disease |
| ASS1 | Argininosuccinate synthase 1, involved in arginine-proline metabolism; dysregulated in mesangioproliferative glomerulopathies | Metabolic biomarker and potential target |
| PCK1 | Phosphoenolpyruvate carboxykinase 1, key metabolic enzyme dysregulated in mesangioproliferative glomerulopathies | Links gluconeogenesis and proliferation |
| CBR3 | Carbonyl reductase 3, metabolic mediator in mesangioproliferative glomerulopathies | Potential metabolic regulator |
| PDGF | Platelet-derived growth factor, potent mitogen for mesangial cells | Classic target for antiproliferative therapy |
| bFGF | Basic fibroblast growth factor, stimulates mesangial cell proliferation | Used in in vitro proliferation assays |
| IL-1 | Interleukin-1, proinflammatory cytokine that promotes mesangial proliferation | Cytokine network modulator |
| IL-6 | Interleukin-6, cytokine involved in mesangial cell growth regulation | Marker of inflammatory glomerular injury |
| TGF-beta | Transforming growth factor-beta, dual role: early proliferation, later antiproliferation and matrix accumulation | Context-dependent regulator |
| mROS | Mitochondrial reactive oxygen species, signaling molecules that enhance proliferation via YY1/HIF-1alpha | Target for antioxidant strategies |
| Cyclin D1 | Cell cycle regulator that promotes G1/S transition in proliferating mesangial cells | Readout of proliferative status |
| CDK4/6 | Cyclin-dependent kinases that drive cell cycle progression | Pharmacological targets for antiproliferative drugs |
| p27Kip1 | Cyclin-dependent kinase inhibitor that restrains mesangial proliferation | Negative regulator and tumor suppressor |
| p53 | Tumor suppressor that can induce apoptosis in mesangial cells | Modulator of resolution phase |
| MMP-2 | Matrix metalloproteinase-2, involved in matrix remodeling after proliferation | Marker of resolution and sclerosis |
| TIMP-1 | Tissue inhibitor of metalloproteinases-1, counteracts MMPs and promotes matrix accumulation | Indicator of progressive glomerular injury |
How Is regulation of glomerular mesangial cell proliferation Regulated?
The regulation of glomerular mesangial cell proliferation is a highly integrated process involving extracellular growth factors, intracellular signaling cascades, transcription factors, metabolic pathways and redox signals. Positive regulators include PDGF, bFGF, IL-1, IL-6, YY1, HIF-1alpha, mROS and cyclin/CDK complexes. Negative regulators include NR4A1, p27Kip1, p53 and, in later stages, TGF-beta, which can inhibit proliferation and promote matrix accumulation. Metabolic enzymes such as ASS1, PCK1 and CBR3 also modulate proliferation through arginine-proline metabolism. The balance between these opposing forces determines net mesangial cellularity and the progression to glomerulosclerosis.
regulation of glomerular mesangial cell proliferation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NR4A1 | Mesangial proliferative glomerulonephritis | Knockout and knock-in mouse models; mesangial cell lines with NR4A1 overexpression or degradation-resistant mutants |
| YY1 | Diabetic kidney disease | Conditional knockout in mesangial cells; YY1 overexpression in vitro |
| HIF-1alpha | Diabetic kidney disease | HIF-1alpha knockout or point-mutation models; hypoxia mimetics |
| ASS1 | Mesangioproliferative glomerulopathies | Metabolic flux assays; ASS1 knockout and overexpression in mesangial cells |
| PCK1 | Mesangioproliferative glomerulopathies | PCK1 knockout mice; gluconeogenesis assays |
Mesangial proliferative glomerulonephritis
Mesangial proliferative glomerulonephritis is characterized by excessive proliferation of mesangial cells and matrix expansion, leading to glomerular injury. NR4A1 degradation promotes mesangial proliferation, and stabilizing NR4A1 with Bruceine A alleviates the disease in experimental models. This highlights the therapeutic potential of targeting regulators of GO:0072124.
Diabetic kidney disease
In early diabetic kidney disease, the YY1/HIF-1alpha/mROS positive-feedback loop exacerbates glomerular mesangial cell proliferation, contributing to glomerular hyperfiltration and injury. Targeting this loop may slow disease progression.
IgA nephropathy
Single-nucleus RNA-seq in IgA nephropathy has revealed cellular trajectories from onset to chronic kidney disease, including mesangial cell states associated with proliferation. This provides a roadmap for identifying proliferative signatures in human disease.
Progressive glomerular injury and chronic kidney disease
Sustained mesangial cell proliferation contributes to progressive glomerular injury and chronic kidney disease through matrix accumulation and glomerulosclerosis. Understanding the regulation of this process is key to developing therapies that prevent irreversible kidney damage.
From regulation of glomerular mesangial cell proliferation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene increase mesangial cell proliferation? | CRISPR knockout in primary mesangial cells or immortalized mesangial cell lines |
| Does a specific point mutation in a regulator alter its function? | CRISPR point-mutation knock-in in mesangial cells |
| Does overexpression of a protective gene reduce proliferation? | Lentiviral or CRISPR-mediated overexpression in mesangial cells |
| Does a tagged version of the protein localize correctly? | CRISPR knock-in of fluorescent or epitope tags |
| Does the gene regulate proliferation in vivo? | Conditional knockout or knock-in mouse models of glomerular disease |
| Can we identify novel regulators in an unbiased way? | CRISPR library screening in mesangial cells under proliferative stimuli |
How to Study the regulation of glomerular mesangial cell proliferation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Thymidine incorporation | DNA synthesis | Quantifying mesangial cell proliferation in vitro |
| Ki-67 staining | Proliferative index | Assessing proliferation in tissue sections |
| Single-nucleus RNA-seq | Transcriptomic profiles of individual nuclei | Mapping cellular trajectories in IgA nephropathy |
| Proteomics | Protein expression and modifications | Identifying dysregulated metabolic enzymes |
| Metabolomics | Metabolite levels | Linking arginine-proline metabolism to proliferation |
| CRISPR knockout | Loss-of-function phenotypes | Testing candidate gene causality |
| CRISPR knock-in | Precise mutations or tags | Modeling point mutations or tagging endogenous proteins |
| Western blot | Protein expression and signaling | Validating pathway activation |
In vitro mesangial cell proliferation assays
Primary or immortalized mesangial cells can be stimulated with growth factors such as PDGF or bFGF, and proliferation measured by thymidine incorporation, MTT, or Ki-67 staining. These assays are foundational for testing candidate regulators identified by CRISPR screens.
Single-nucleus RNA-seq and transcriptomics
Single-nucleus RNA-seq of kidney biopsies from IgA nephropathy patients has revealed cellular trajectories and mesangial cell states associated with proliferation. This method can identify novel markers and regulators of GO:0072124 in human disease.
Proteomics and metabolic profiling
Proteomic and metabolomic analyses have identified dysregulation of ASS1, PCK1 and CBR3 in mesangioproliferative glomerulopathies, linking arginine-proline metabolism to proliferation. These approaches can uncover metabolic vulnerabilities.
CRISPR-based functional genomics
CRISPR knockout, point-mutation, knock-in and overexpression models allow causal testing of candidate genes in mesangial cells. For example, protecting NR4A1 from ubiquitin degradation via point mutation alleviates mesangial proliferative glomerulonephritis in models.
How CRISPR Can Be Used to Study GO:0072124 regulation of glomerular mesangial cell proliferation
Knockout
CRISPR knockout of candidate genes in mesangial cells or mouse models can determine whether a gene is necessary for proliferation. For example, knockout of NR4A1 would be expected to exacerbate proliferation, while knockout of YY1 might reduce it.
Point Mutation
Point mutations can mimic disease-associated variants or stabilize proteins. For instance, mutations that prevent ubiquitination of NR4A1 protect it from degradation and alleviate mesangial proliferative glomerulonephritis.
Knock-in
Knock-in of fluorescent or epitope tags allows visualization and quantification of endogenous proteins in mesangial cells. This is useful for tracking NR4A1 localization or YY1 dynamics.
Overexpression
Overexpression of protective genes such as NR4A1 or dominant-negative mutants of proliferative drivers can suppress mesangial cell proliferation. This approach is valuable for validating therapeutic targets.
How EDITGENE Supports regulation of glomerular mesangial cell proliferation Research
Researchers studying regulation of glomerular mesangial cell proliferation-related genes often need to determine whether a candidate gene is causally involved in the proliferative response. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such functional studies in mesangial cells and animal models.
Contact EDITGENE today to design your custom CRISPR model for regulation of glomerular mesangial cell proliferation research.
Frequently Asked Questions About regulation of glomerular mesangial cell proliferation
What is GO:0072124?
GO:0072124 is the Gene Ontology term for regulation of glomerular mesangial cell proliferation, defined as any process that modulates the frequency, rate or extent of mesangial cell proliferation.
What genes are involved in regulation of glomerular mesangial cell proliferation?
Key genes include NR4A1, YY1, HIF-1alpha, ASS1, PCK1, CBR3, PDGF, bFGF, IL-1, IL-6 and TGF-beta, among others.
How is mesangial cell proliferation regulated?
It is regulated by a balance of growth factors, cytokines, transcription factors, metabolic signals and cell cycle regulators.
What diseases are associated with dysregulated mesangial cell proliferation?
Mesangial proliferative glomerulonephritis, diabetic kidney disease, IgA nephropathy and progressive glomerular injury leading to chronic kidney disease.
What is the role of NR4A1 in mesangial proliferation?
NR4A1 protects against mesangial proliferation; its ubiquitin-mediated degradation promotes proliferation, and stabilizing it alleviates disease.
How does the YY1/HIF-1alpha/mROS loop affect mesangial cells?
This positive-feedback loop exacerbates glomerular mesangial cell proliferation in early diabetic kidney disease.
What experimental models are used to study GO:0072124?
In vitro mesangial cell cultures, animal models of glomerulonephritis, single-nucleus RNA-seq and CRISPR-edited cells or mice.
Can CRISPR be used to study mesangial cell proliferation?
Yes, CRISPR knockout, point mutation, knock-in and overexpression models are powerful tools to test causality of candidate genes.
What is the significance of metabolic enzymes in mesangioproliferative glomerulopathies?
Dysregulation of ASS1, PCK1 and CBR3 links arginine-proline metabolism to mesangial proliferation and disease.
How can I find novel regulators of mesangial cell proliferation?
CRISPR library screening combined with single-cell transcriptomics and proteomics can identify novel regulators.
Conclusion
GO:0072124, regulation of glomerular mesangial cell proliferation, is a critical biological process in kidney health and disease. Its dysregulation drives mesangial proliferative glomerulonephritis, diabetic kidney disease and IgA nephropathy, making it a prime target for therapeutic intervention. Advances in CRISPR gene editing, single-nucleus RNA-seq and metabolic profiling are accelerating the discovery of key regulators and their mechanisms. EDITGENE's comprehensive services empower researchers to dissect this process with precision and translate findings into new treatments.
References
- 1. Hu H et al.. 2025. Bruceine A protects nuclear receptor 4A1 from ubiquitin-degradation to alleviate mesangial proliferative glomerulonephritis.. Signal Transduct Target Ther 10(1):397 PMID: 41345104
- 2. Floege J et al.. 1991. Regulation of mesangial cell proliferation.. Am J Kidney Dis 17(6):673-6 PMID: 2042647
- 3. Doi T. 2001. The contribution of mesangial cell proliferation to progressive glomerular injury.. J Med Invest 48(1-2):1-4 PMID: 11286009
- 4. Floege J et al.. 1993. Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo.. Kidney Int Suppl 39:S47-54 PMID: 8468926
- 5. You JP et al.. 2025. Single nucleus RNA-seq reveals the process from onset to chronic kidney disease in IgA nephropathy.. Sci Rep 15(1):22780 PMID: 40592877
- 6. Yang TT et al.. 2025. YY1/HIF-1α/mROS positive-feedback loop exacerbates glomerular mesangial cell proliferation in mouse early diabetic kidney disease.. Acta Pharmacol Sin 46(7):1974-1989 PMID: 40038466
- 7. He J et al.. 2026. Dysregulation of argininosuccinate synthase 1, phosphoenolpyruvate carboxykinase 1, and carbonyl reductase 3: Key arginine-proline metabolic mediators in mesangioproliferative glomerulopathies.. Int J Biol Macromol 337(Pt 2):149479 PMID: 41352509
- 8. Couser WG. 1993. Pathogenesis of glomerulonephritis.. Kidney Int Suppl 42:S19-26 PMID: 8361123
